Identification
- Generic Name
- Alisertib
- DrugBank Accession Number
- DB05220
- Background
Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Alisertib (DB05220)
- Weight
- Average: 518.93
Monoisotopic: 518.115711 - Chemical Formula
- C27H20ClFN4O4
- Synonyms
- Alisertib
- External IDs
- MLN 8237
- MLN-8237
- MLN8237
Pharmacology
- Indication
For the treatment of various forms of cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAurora kinase A inhibitorregulatorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Alisertib sodium T76P158V9D 1208255-63-3 WLPXWQKMVACWII-UHFFFAOYSA-M
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzazepines
- Sub Class
- Not Available
- Direct Parent
- Benzazepines
- Alternative Parents
- O-methoxybenzoic acids and derivatives / Benzoic acids / Methoxyanilines / Benzoyl derivatives / Phenoxy compounds / Methoxybenzenes / Anisoles / Azepines / Fluorobenzenes / Alkyl aryl ethers show 16 more
- Substituents
- Alkyl aryl ether / Amine / Amino acid / Amino acid or derivatives / Aminopyrimidine / Aniline or substituted anilines / Anisole / Aromatic heteropolycyclic compound / Aryl chloride / Aryl fluoride show 37 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- T66ES73M18
- CAS number
- 1028486-01-2
- InChI Key
- ZLHFILGSQDJULK-UHFFFAOYSA-N
- InChI
- InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
- IUPAC Name
- 4-{[13-chloro-10-(2-fluoro-6-methoxyphenyl)-3,5,9-triazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2,4,6,9,11,13-heptaen-4-yl]amino}-2-methoxybenzoic acid
- SMILES
- COC1=CC(NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C2=C(OC)C=CC=C2F)=CC=C1C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 24771867
- PubChem Substance
- 347827718
- ChemSpider
- 24700147
- BindingDB
- 50277545
- ChEBI
- 125628
- ChEMBL
- CHEMBL483158
- ZINC
- ZINC000040939534
- PharmGKB
- PA166165015
- PDBe Ligand
- A5B
- Wikipedia
- Alisertib
- PDB Entries
- 5ia0
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Completed Treatment Refractory Peripheral T-Cell Lymphoma / Relapsed Peripheral T-Cell Lymphoma 1 2 Active Not Recruiting Treatment Atypical teratoid/rhabdoid tumour of CNS / Malignant Rhabdoid Tumors (MRT) 1 2 Active Not Recruiting Treatment Breast Cancer Stage IIIc / Breast Cancer, Stage III / Breast Cancer, Stage IIIB / Carcinoma Breast Stage IV / Estrogen Receptor Status / HER2 negative / Invasive Breast Carcinoma / Postmenopausal / Stage IIIA Breast Cancer 1 2 Active Not Recruiting Treatment Breast Cancer / Breast Carcinoma / Breast Tumor / Malignant Breast Neoplasm 1 2 Completed Treatment Acute Myeloid Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00149 mg/mL ALOGPS logP 5 ALOGPS logP 5.5 Chemaxon logS -5.5 ALOGPS pKa (Strongest Acidic) 4.28 Chemaxon pKa (Strongest Basic) 3.01 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 105.93 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 137.21 m3·mol-1 Chemaxon Polarizability 52.31 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 213.89894 predictedDeepCCS 1.0 (2019) [M+H]+ 216.29451 predictedDeepCCS 1.0 (2019) [M+Na]+ 222.20703 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- InhibitorRegulator
- General Function
- Protein serine/threonine/tyrosine kinase activity
- Specific Function
- Mitotic serine/threonine kinases that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role i...
- Gene Name
- AURKA
- Uniprot ID
- O14965
- Uniprot Name
- Aurora kinase A
- Molecular Weight
- 45809.03 Da
References
- de Groot CO, Hsia JE, Anzola JV, Motamedi A, Yoon M, Wong YL, Jenkins D, Lee HJ, Martinez MB, Davis RL, Gahman TC, Desai A, Shiau AK: A Cell Biologist's Field Guide to Aurora Kinase Inhibitors. Front Oncol. 2015 Dec 21;5:285. doi: 10.3389/fonc.2015.00285. eCollection 2015. [Article]
Drug created at October 21, 2007 22:24 / Updated at June 30, 2022 21:24